XML 45 R23.htm IDEA: XBRL DOCUMENT v3.25.4
Related Parties
 12 Months Ended
Dec. 31, 2025
Related Party Transactions [Abstract]  
Related Parties

12. Related Parties

Third Rock Ventures

During the year ended December 31, 2024, the Company issued a total of 12.4 million shares of its Series B Convertible Preferred Stock to Third Rock Ventures VI, L.P., a holder of more than 5% of the Company’s outstanding capital stock, during the second tranche closing in May 2024, for cash proceeds of $15.3 million. These shares were converted to shares of the Company's common stock upon the consummation of its IPO in October 2024. No shares were issued during the year ended December 31, 2025.

In August 2021, the Company entered into a service agreement with Third Rock Ventures, LLC (“TRV”), a holder of more than 5% of the Company’s outstanding capital stock, (the “TRV service agreement”) under which TRV provides consulting services to the Company. For the year ended December 31, 2024, the Company recorded expense of $0.3 million for such services as general and administrative expenses in the Company’s statements of operations and comprehensive loss. As of December 31, 2024, $0.1 million of expense related to TRV was recorded in accrued expenses and other current liabilities. There was no expense recorded in accrued expenses and other current liabilities and no outstanding accounts payable to TRV at December 31, 2025.

The Company's former interim Chief Medical Officer, and also a current member of the Company's board of directors, was designated to the Company's board of directors by TRV and is affiliated with TRV. He did not receive any cash compensation from the Company for his service as its interim Chief Medical Officer as his services were provided to the Company through the TRV service agreement.

Of the total fees the Company incurred under the TRV service agreement for the year ended December 31, 2024, $0.2 million was attributed to consulting services provided by the board member. Additionally, as compensation for his services as the Company's interim Chief Medical Officer, the Company granted him options to purchase 23,227 shares during the year ended December 31, 2024 at the exercise price of $2.76 per share. The board member ceased serving as interim Chief Medical Officer in September 2024.

In December 2024, the Company entered into a separate consulting agreement with the board member, under which he may provide up to $9,500 of consulting services per month, which are also provided to the Company through the TRV service agreement. For the year ended December 31, 2025, the Company recorded expense of $0.1 million for such consulting services. As of December 31, 2025, there was a minimal expense recorded in accrued expenses and other current liabilities and a minimal outstanding accounts payable to the board member.

RA Capital

During the year ended December 31, 2024, the Company issued a total of 12.2 million shares of its Series B Convertible Preferred Stock to entities affiliated with RA Capital Management, L.P. (collectively, “RA Capital”), which held more than 5% of the Company’s outstanding capital stock, during the second tranche closing in May 2024, for total cash proceeds of $15.0 million. These shares were

converted to shares of the Company's common stock upon the consummation of its IPO in October 2024. No shares were issued during the year ended December 31, 2025.

Samsara BioCapital

During the year ended December 31, 2024, the Company issued a total of 4.3 million shares of its Series B Convertible Preferred Stock to Samsara BioCapital, L.P. (“Samsara BioCapital”), a holder of more than 5% of the Company’s outstanding capital stock, during the second tranche closing in May 2024, for cash proceeds of $5.2 million. These shares were converted to shares of the Company's common stock upon the consummation of its IPO in October 2024. No shares were issued during the year ended December 31, 2025.